gemcitabine – Medxy AI

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A 3-Year Survival Update from the Phase III TOPAZ-1 Study

By MedXY 10/29/2025

The TOPAZ-1 study shows durvalumab combined with gemcitabine and cisplatin improves 3-year overall survival in advanced biliary tract cancer with manageable safety, establishing a new standard of care.

Clinical Updates news Oncology Specialties

Evaluating the Addition of Polymeric Micellar Paclitaxel to Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: Insights from a Phase 3 Randomized Clinical Trial

By MedXY 10/01/2025

A South Korean phase 3 trial found that adding polymeric micellar paclitaxel to gemcitabine and cisplatin did not improve survival for advanced biliary tract cancer, highlighting the challenges of intensified chemotherapy regimens.

Clinical Updates Oncology

Phase III NuTide:121 Trial Shows NUC-1031/Cisplatin Fails to Improve Survival Over Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer

By MedXY 09/20/2025

The NuTide:121 phase III trial compared NUC-1031/cisplatin to gemcitabine/cisplatin in treatment-naïve advanced biliary tract cancer but was terminated early due to lack of survival benefit and increased liver toxicity with NUC-1031.

Clinical Updates news Oncology Specialties

Nab-Paclitaxel Plus Gemcitabine Outperforms mFOLFIRINOX and S-IROX as First-Line Therapy for Metastatic Pancreatic Cancer: Insights from the GENERATE (JCOG1611) Trial

By MedXY 08/01/2025

A large Japanese phase II/III trial shows nab-paclitaxel plus gemcitabine confers longer overall survival and better tolerability compared to mFOLFIRINOX and S-IROX in metastatic pancreatic cancer.